Literature DB >> 21454195

IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).

Robert A Kyle1, Angela Dispenzieri, Shaji Kumar, Dirk Larson, Terry Therneau, S Vincent Rajkumar.   

Abstract

Monoclonal gammopathy of undetermined significance of IgM class (IgM MGUS) was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in Southeastern Minnesota from 1960 to 1994. During long-term follow-up 29 (14%) developed non-Hodgkin lymphoma (n=17), Waldenström's macroglobulinemia (n=6), chronic lymphocytic leukemia (n=3), and AL amyloidosis (n=3) with relative risks of 15-, 262-, 6-, and 16-fold, respectively. The cumulative probability of progression to one of these disorders was 10% at 5 years, 18% at 10 years, and 24% at 15 years, approximately 1.5% per year.Forty-eight patients with SWM were identified at Mayo Clinic from 1974 to 1995. During 285 cumulative person-years of follow-up (median, 15.4 years) 34 (71%) progressed to Waldenström's macroglobulinemia (WM), 1 to AL amyloidosis, and 1 to lymphoma (total, 36 [75%]). The cumulative probability of progressing to WM, amyloidosis, or lymphoma was 6% at 1 year, 39% at 3 years, and 59% at 5 years (12% per year).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454195     DOI: 10.3816/CLML.2011.n.011

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  6 in total

Review 1.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

Review 2.  Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

Authors:  Alexander Grunenberg; Christian Buske
Journal:  Dtsch Arztebl Int       Date:  2017-11-03       Impact factor: 5.594

3.  MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation.

Authors:  Martina Ferrante; Daniela Furlan; Silvia Zibellini; Michela Borriero; Chiara Candido; Nora Sahnane; Silvia Uccella; Elisa Genuardi; Beatrice Alessandria; Benedetta Bianchi; Barbara Mora; Daniele Grimaldi; Irene Defrancesco; Cristina Jiménez; Federica Cavallo; Dario Ferrero; Irene Dogliotti; Michele Merli; Marzia Varettoni; Simone Ferrero; Daniela Drandi
Journal:  Diagnostics (Basel)       Date:  2021-04-26

Review 4.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

5.  Candidate genes of Waldenström's macroglobulinemia: current evidence and research.

Authors:  Giada Bianchi; Antonio Sacco; Shaji Kumar; Giuseppe Rossi; Irene Ghobrial; Aldo Roccaro
Journal:  Appl Clin Genet       Date:  2013-07-17

Review 6.  Waldenström macroglobulinemia treatment algorithm 2018.

Authors:  Morie A Gertz
Journal:  Blood Cancer J       Date:  2018-05-01       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.